Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04051996
Recruitment Status : Suspended (Temporary Recruitment Hold due to COVID-19)
First Posted : August 9, 2019
Last Update Posted : July 2, 2020
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Amer Zeidan, Yale University

Brief Summary:
This multi-center, randomized phase 2 study is designed to evaluate the complete remission (including complete remission with incomplete count recovery) rates of glasdegib in combination with either decitabine on a 5-day or 10-day schedule in patients with newly-diagnosed poor-risk AML who either refuse or are ineligible for intensive therapy.

Condition or disease Intervention/treatment Phase
ACUTE MYELOID LEUKEMIA Drug: Glasdegib Drug: Decitabine Phase 2

Detailed Description:

The primary objective of this multi-center, randomized phase 2 study is to determine the response rates, complete remission (CR) and complete remission with incomplete count recovery (CRi), of glasdegib/DAC5 and glasdegib/DAC10 in patients with newly-diagnosed PrAML.

There are two secondary objectives for this study. The first secondary objective is to evaluate the toxicity and safety profiles of glasdegib/DAC5 and glasdegib/DAC10 in patients with newly-diagnosed PrAML. The other secondary objective is to determine the event-free survival (EFS), relapse-free survival (RFS), overall survival (OS), duration of response, bone marrow mutational clearance, and remission clonality of glasdegib/DAC5 and glasdegib/DAC10 in patients with newly-diagnosed PrAML.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Randomized, Parallel-arm, Phase 2 Clinical Trial of the Combination of Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia Who Are Unfit for or Refuse Intensive Chemotherapy (GLAD-AML)
Actual Study Start Date : September 27, 2019
Estimated Primary Completion Date : September 15, 2021
Estimated Study Completion Date : September 15, 2022


Arm Intervention/treatment
Experimental: DAC5
Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
Drug: Glasdegib
Glasdegib will be administered at the starting dose of 100 mg orally once daily.

Drug: Decitabine
Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.

Experimental: DAC10
Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
Drug: Glasdegib
Glasdegib will be administered at the starting dose of 100 mg orally once daily.

Drug: Decitabine
Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.




Primary Outcome Measures :
  1. CR/CRi [ Time Frame: Up to 2 years ]
    The complete remission (CR) and complete remission with incomplete count recovery (CRi) combined rate will be defined by the 2017 European LeukemiaNet (ELN) AML response criteria.


Secondary Outcome Measures :
  1. OS [ Time Frame: Up to 2 years ]
    Overall survival (OS) is defined as the time from date of first study treatment to date of death due to any cause.

  2. EFS [ Time Frame: Up to 2 years ]
    Event-free survival (EFS) will be monitored up to 2 years.

  3. RFS [ Time Frame: Up to 2 years ]
    Relapse-free survival (RFS) will be monitored up to 2 years.

  4. Time to CR/CRi [ Time Frame: Up to 2 years ]
    The time to complete remission (CR) and complete remission with incomplete count recovery (CRi) will be collected as a secondary outcome.

  5. duration of CR/CRi [ Time Frame: Up to 2 years ]
    The duration of complete remission (CR) and complete remission with incomplete count recovery (CRi) will be collected as a secondary outcome.

  6. bone marrow mutational clearance [ Time Frame: Up to 2 years ]
    Bone marrow mutational clearance of frequently-mutated genes in AML (e.g. NPM1, CEBPA, DNMT3A, RUNX1, TET2, IDH1/2) via next-generation DNA sequencing will be monitored up to 2 years.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a morphologically-confirmed diagnosis of AML according to WHO 2016 classification with poor-risk disease as defined by the cytogenetic or molecular abnormalities (excluding FLT3-mutated AML).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.
  • Adequate Renal Function:

    a. Calculated creatinine clearance (determined by MDRD) ≥50mL/min/1.73m2, or serum creatinine <1.5x upper limit of normal (ULN);

  • Adequate Liver Function:

    1. Total serum bilirubin ≤ 2.0 x ULN (unless the bilirubin is principally unconjugated and there is strong suspicion of sub-clinical hemolysis or the patient has documented Gilbert's disease);
    2. Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 3.0 x ULN;
    3. Alkaline phosphatase ≤ 3.0 x ULN.
  • Serum or urine pregnancy test (for female patients of childbearing potential) with a minimum sensitivity of 25 IU/L or equivalent units of human chorionic gonadotropin (HCG) negative at screening.
  • Males and female patients both of childbearing potential and at risk for pregnancy must agree to use two highly effective method(s) of contraception throughout the study and for 180 days after the last dose of decitabine and the last dose of glasdegib, whichever occurs later.
  • Female patients who are not of childbearing potential (i.e. meet at least 1 of the following criteria):

    1. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    2. Have medically confirmed ovarian failure;
    3. Have achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed by having a serum follicle stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal women.

Exclusion Criteria:

  • Patients who are candidates for and willing to receive intensive induction chemotherapy.
  • Prior use of a hypomethylating agent.
  • Prior use of cytotoxic chemotherapy for any myeloid malignancy (prior immunosuppressive therapy is permitted provided that treatment is stopped within 8 weeks from study entry; hydroxyurea is allowed through the end of cycle 1 on study).
  • Previous hematopoietic stem cell transplant.
  • Prior treatment with a licensed or experimental smoothened inhibitor (SMOi) and/or hypomethylating agent (HMA).
  • Participation in a clinical study involving an investigational drug(s) (Phases 1-4) within 4 weeks prior to study entry or within 5 half-lives of the investigational agent, whichever is greater.
  • Major surgery or radiation within 12 weeks prior to study entry.
  • Patients known to be refractory to platelet or packed red cell transfusions as per institutional guidelines, or who are known to refuse or who are likely to refuse blood product support.
  • Treatment with hematopoietic growth factors including: erythropoietin, granulocyte colony stimulating factor (G-CSF), and granulocyte macrophage colony stimulating factor (GM-CSF), or thrombopoietin receptor agonists within 3 weeks prior to study entry.
  • Any ongoing medical condition requiring chronic use of moderate to high dose steroids (defined as ≥10 mg/day of prednisone or equipotent dose of another corticosteroid).
  • Any anti-cancer treatment within 2 weeks prior to study entry (including hydroxyurea as above).
  • Current use or anticipated requirement for drugs that are known moderate to strong CYP3A4 inducers (Appendix 2).
  • Presence of concurrent active malignancy requiring active systemic therapy
  • Patients with known active, uncontrolled bacterial, fungal or viral infection, including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
  • Known uncontrolled central nervous system (CNS) involvement.
  • Poorly-controlled active medical conditions that as per investigator judgement would interfere with the conduct of the study.
  • Active cardiac dysrhythmias of NCI CTCAE Grade ≥2 (e.g. atrial fibrillation) or QTcF interval >470 msec.
  • Pregnant or breastfeeding female patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04051996


Locations
Layout table for location information
United States, Connecticut
Yale Cancer Center/Smilow
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Yale University
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Amer M Zeidan, MBBS Yale University - MEDCCC Hematology-Section
Layout table for additonal information
Responsible Party: Amer Zeidan, Associate Professor of Internal Medicine (Hematology), Yale University
ClinicalTrials.gov Identifier: NCT04051996    
Other Study ID Numbers: 2000024738
First Posted: August 9, 2019    Key Record Dates
Last Update Posted: July 2, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Decitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors